State Street Corp Has $3.78 Million Stock Holdings in XOMA Co. (NASDAQ:XOMA)

State Street Corp lifted its holdings in shares of XOMA Co. (NASDAQ:XOMA) by 1.2% in the 3rd quarter, HoldingsChannel reports. The fund owned 142,857 shares of the biotechnology company’s stock after purchasing an additional 1,754 shares during the period. State Street Corp’s holdings in XOMA were worth $3,783,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in XOMA. Ellsworth Advisors LLC purchased a new stake in shares of XOMA in the third quarter worth approximately $516,000. Bank of New York Mellon Corp grew its holdings in XOMA by 3.2% during the second quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock worth $1,484,000 after buying an additional 1,968 shares in the last quarter. Rhumbline Advisers raised its position in XOMA by 16.0% in the 2nd quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock valued at $230,000 after buying an additional 1,334 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its stake in XOMA by 95.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock valued at $43,000 after acquiring an additional 795 shares in the last quarter. Institutional investors and hedge funds own 95.92% of the company’s stock.

XOMA Stock Performance

Shares of XOMA opened at $26.09 on Tuesday. XOMA Co. has a 1 year low of $18.57 and a 1 year high of $35.00. The company has a debt-to-equity ratio of 1.28, a current ratio of 7.52 and a quick ratio of 7.52. The stock’s fifty day moving average price is $29.76 and its two-hundred day moving average price is $27.87. The firm has a market cap of $307.42 million, a PE ratio of -7.50 and a beta of 0.88.

Insider Buying and Selling at XOMA

In other news, CEO Owen Hughes sold 21,881 shares of the business’s stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $29.95, for a total value of $655,335.95. Following the sale, the chief executive officer now owns 34,979 shares of the company’s stock, valued at $1,047,621.05. The trade was a 38.48 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 7.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. HC Wainwright reiterated a “buy” rating and issued a $123.00 price objective on shares of XOMA in a research note on Friday, December 13th. StockNews.com cut XOMA from a “hold” rating to a “sell” rating in a research report on Friday.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.